| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,746 |
10,327 |
$1.42M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,882 |
6,588 |
$1.28M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
275 |
264 |
$894K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
40,642 |
36,638 |
$815K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,028 |
993 |
$164K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
420 |
408 |
$139K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14,300 |
12,162 |
$87K |
| 80053 |
Comprehensive metabolic panel |
11,207 |
10,226 |
$81K |
| J3490 |
Unclassified drugs |
16,698 |
9,654 |
$72K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,748 |
1,620 |
$38K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
372 |
355 |
$31K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
711 |
682 |
$26K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
301 |
296 |
$22K |
| 81003 |
|
5,457 |
4,295 |
$16K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
12 |
12 |
$15K |
| 71045 |
Radiologic examination, chest; single view |
343 |
326 |
$14K |
| 97597 |
|
441 |
251 |
$14K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
342 |
261 |
$12K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
139 |
134 |
$12K |
| 81001 |
|
3,911 |
3,763 |
$11K |
| 70450 |
Computed tomography, head or brain; without contrast material |
51 |
50 |
$11K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
804 |
212 |
$10K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
43 |
41 |
$9K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
17 |
12 |
$9K |
| C1889 |
Implantable/insertable device, not otherwise classified |
28 |
27 |
$9K |
| 36415 |
Collection of venous blood by venipuncture |
4,024 |
3,532 |
$8K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
769 |
178 |
$7K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
313 |
293 |
$7K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,582 |
407 |
$7K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
713 |
199 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
95 |
92 |
$5K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
473 |
448 |
$5K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
31 |
29 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
280 |
264 |
$4K |
| 83735 |
|
741 |
716 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
81 |
79 |
$4K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
39 |
37 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
211 |
134 |
$3K |
| J2704 |
Injection, propofol, 10 mg |
312 |
266 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
97 |
89 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
53 |
52 |
$2K |
| 85027 |
|
252 |
236 |
$2K |
| 73610 |
|
41 |
37 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
366 |
333 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
145 |
143 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
98 |
92 |
$2K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
16 |
15 |
$2K |
| 81025 |
|
207 |
188 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
12 |
12 |
$2K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
34 |
29 |
$1K |
| 73030 |
|
27 |
24 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
313 |
297 |
$1K |
| 83690 |
|
178 |
167 |
$1K |
| 73630 |
|
14 |
14 |
$1K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
26 |
25 |
$1K |
| 97016 |
|
134 |
37 |
$1K |
| 83655 |
|
59 |
54 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
31 |
27 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
31 |
27 |
$1K |
| 97803 |
|
52 |
45 |
$781.45 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
38 |
38 |
$702.58 |
| 84484 |
|
76 |
66 |
$647.50 |
| 82607 |
|
26 |
25 |
$643.23 |
| 82746 |
|
26 |
25 |
$627.53 |
| 73140 |
|
13 |
13 |
$600.34 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
66 |
61 |
$573.29 |
| 85652 |
|
196 |
185 |
$507.93 |
| 81002 |
|
113 |
90 |
$463.46 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
160 |
150 |
$424.78 |
| 86140 |
|
89 |
83 |
$407.50 |
| 84443 |
Thyroid stimulating hormone (TSH) |
38 |
38 |
$406.20 |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
48 |
36 |
$375.48 |
| 80061 |
Lipid panel |
29 |
29 |
$367.40 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
151 |
135 |
$357.55 |
| 73562 |
|
13 |
12 |
$341.36 |
| 20610 |
|
16 |
12 |
$283.31 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
43 |
43 |
$280.99 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
53 |
52 |
$226.22 |
| 85651 |
|
69 |
66 |
$216.95 |
| 90686 |
|
105 |
100 |
$213.46 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
24 |
24 |
$209.57 |
| 86592 |
|
42 |
41 |
$201.78 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
12 |
$200.82 |
| 83540 |
|
26 |
25 |
$193.98 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
27 |
27 |
$132.99 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
42 |
38 |
$119.98 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
16 |
15 |
$77.52 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
13 |
12 |
$45.24 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
25 |
25 |
$21.62 |
| 82962 |
|
15 |
15 |
$17.52 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
41 |
36 |
$0.65 |
| A9270 |
Non-covered item or service |
79 |
50 |
$0.19 |